2018-02-23 18:55 ET - News Release

Mr. Stephen Hall of Emerald Health Sciences reports

On Feb. 14, 2018, Emerald Health Sciences Inc. sold, through a secondary offering, two million common shares of Emerald Health Therapeutics Inc.

Immediately before the transaction that triggered the requirement to file this report, the acquiror had ownership of 43,156,555 shares, representing approximately 38.79 per cent of then issued and outstanding shares. Following the transaction that triggered the requirement to file this report, the acquiror held direct ownership of 41,156,555 shares, representing approximately 35.10 per cent of the issued and outstanding shares. The acquiror also holds 8,489,451 common share purchase warrants. Assuming the exercise of the warrants, the acquiror would own 49,646,006 shares, representing approximately 39.49 per cent of the issued and outstanding shares (on a partially diluted basis giving effect only to the exercise of the warrants).

The acquiror disposed of the shares for investment purposes. The acquiror may sell additional shares either on the open market or through private dispositions in the future depending on market conditions, reformulation of plans and/or other relevant factors.

This news release is being issued pursuant to Part 3 of National Instrument 62-103 (the Early Warning System and Related Take-Over Bid and Insider Reporting Issues) of the Canadian Securities Administrators. A copy of the report filed by the acquiror in connection with the acquisition of the shares is available on the issuer's SEDAR profile, and it can also be obtained directly from the acquiror.